What is the stepwise approach to adding anti‑anginal medications for a patient with persistent angina despite optimal therapy?

Stepwise Approach to Adding Anti-Anginal Medications

Start with a beta-blocker as first-line therapy, then add ivabradine, amlodipine, or long-acting nitrates as second-line agents if angina persists, and proceed to coronary revascularization if symptoms remain uncontrolled on two drugs. 1

Step 1: First-Line Therapy

Beta-blockers are the preferred initial treatment because they not only relieve angina but also reduce the risk of heart failure hospitalization and premature death (Class I, Level A recommendation). 1

If Beta-Blockers Are Not Tolerated:

Choose from these alternatives based on patient characteristics:

• Ivabradine (Class IIa, Level A): For patients in sinus rhythm with heart rate ≥70 bpm who cannot tolerate beta-blockers—proven effective and safe in heart failure. 1

• Amlodipine (Class IIa, Level A): Effective antianginal treatment that is safe in heart failure, particularly useful in patients with concurrent hypertension. 1

• Oral or transcutaneous nitrates (Class IIa, Level A): Effective and safe in heart failure, though require nitrate-free intervals to avoid tolerance. 1

• Ranolazine or nicorandil (Class IIb, Level C): May be considered, but safety in heart failure is uncertain. 1

Step 2: Add Second Anti-Anginal Drug

When angina persists despite optimal first-line therapy, add one of the following (all Class I, Level A recommendations):

• Ivabradine: Particularly effective when added to beta-blockers—more efficient than uptitrating beta-blockers alone. 1, 2

• Amlodipine: Can be safely combined with beta-blockers for additive symptom control. 1

• Long-acting nitrates: Provide additional symptom relief but require nitrate-free intervals. 1

• Ranolazine or nicorandil (Class IIb, Level C): May be considered as add-on therapy, though evidence is weaker. 1

Critical Drug Combinations to AVOID:

• Never combine diltiazem or verapamil with beta-blockers or in patients with heart failure—they worsen left ventricular function (Class III, Level B). 1

• Never combine ivabradine with non-dihydropyridine calcium channel blockers or strong CYP3A4 inhibitors. 3

• Avoid combining ivabradine, ranolazine, and nicorandil together—unknown safety profile (Class III, Level C). 1

• Do not combine nicorandil with nitrates—no additional efficacy (Class III, Level C). 1

Step 3: Coronary Revascularization or Third Drug

Coronary revascularization is recommended when angina persists despite two antianginal drugs (Class I, Level A). 1

Alternative to Revascularization:

A third antianginal drug may be considered (Class IIb, Level C) if revascularization is not feasible, selecting from the agents listed above while strictly avoiding the contraindicated combinations. 1

Special Considerations by Comorbidity

Left Ventricular Dysfunction/Heart Failure:

• Beta-blockers are mandatory for mortality benefit. 1, 2
• Add ivabradine if heart rate remains >70 bpm despite optimal beta-blockade—the SHIFT trial demonstrated prognostic benefit. 2
• Avoid diltiazem and verapamil entirely—they worsen heart failure. 1

Atrial Fibrillation:

• Use beta-blockers or non-dihydropyridine calcium channel blockers for rate control. 2
• Ivabradine is contraindicated—ineffective in atrial fibrillation and may increase arrhythmia incidence. 2
• Consider adding ranolazine—suppresses supraventricular arrhythmias. 2

Hypertension:

• Prefer beta-blockers or dihydropyridine calcium channel blockers. 2
• Do not reduce blood pressure below 130/80 mmHg—J-curve phenomenon increases cardiovascular risk in coronary artery disease. 2

Diabetes:

• Use vasodilating beta-blockers (carvedilol, nebivolol) to avoid metabolic complications. 2
• Ranolazine has favorable effects on glycated hemoglobin. 2, 4

Common Pitfalls to Avoid

• Do not use triple therapy indiscriminately—it may be deleterious and no more effective than dual therapy. 5
• Ensure nitrate-free intervals of 10-14 hours to prevent tolerance development. 6, 5
• Avoid ivabradine doses >7.5 mg twice daily—higher doses in the SIGNIFY trial showed potential harm. 2
• Never assume beta-blockers are contraindicated in diabetes or COPD—they are safe and effective when properly selected. 1